Fig. 7: c-Jun predicts tamoxifen therapy outcomes in ER-positive BC patients. | Cell Death & Disease

Fig. 7: c-Jun predicts tamoxifen therapy outcomes in ER-positive BC patients.

From: Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer

Fig. 7

a Representative IHC staining of pS63-c-Jun (upper) and CPT1A (lower) proteins in tumour tissues from ER-positive BC patients received tamoxifen therapy with or without recurrence after. b Statistical analysis of the histoscore of pS63-c-Jun (upper) and CPT1A (lower) proteins in tumour tissues from ER-positive BC patients received tamoxifen therapy with or without recurrence. NR, non-recurrence; R, recurrence. Unpaired Student’s t test; **P < 0.01. c Correlations between pS63-c-Jun and CPT1A protein levels in ER-positive BC tissues. Pearson correlation coefficient for statistical analysis. d The heatmap illustrates the association of different clinical characteristics in ER-positive BC patients with high and low expression of pS63-c-Jun. e The heatmap illustrates the association of different clinical characteristics in ER-positive BC patients with high and low expression of CPT1A. Statistical significance was assessed by the Chi-square test in (d, e). f Recurrence-free survival (RFS) was compared between patients with high and low expression of pS63-c-Jun. g RFS was compared between patients with high and low expression of CPT1A. Log-rank test in (f, g); HR, Hazard ratio. h Model depicting the role of the JNK/c-Jun-CPT1A-FAO axis in driving tamoxifen resistance in ER-positive BC.

Back to article page